Stock of interest

December 11, 2007

Osiris Therapeutics

Shares rose 79 cents, or 6.4 percent, to $13.12. The Columbia-based developer of treatments using adult stem cells said its experimental therapy Prochymal was given fast-track review by the FDA.

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.